Going forward, Celltrion is expected to continue its current strategy, aiming to have a total of 23 biosimilar products by 2030, covering therapeutic areas such as immunology and oncology. Leveraging ...

A ctDNA-guided approach can help identify when patients with HR-positive advanced breast cancer are developing an ESR1 ...

LONDON, GREATER LONDON, UNITED KINGDOM, June 5, 2025 /EINPresswire.com/ -- The Business Research Company’s Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts ...

President Donald Trump's tariff-induced stock swoon rolled out the red carpet for investors to snag high-quality stocks at a ...

Jefferies reaffirms its Buy rating on Pfizer and sticks to a $33 target, calling the stock undervalued at $23.35. Their ...

A simple blood test could help breast cancer patients get the proper treatment earlier, potentially halving their risk of ...

A combination of BRAF and MEK inhibitors plus immunotherapy improved progression-free but not overall survival, compared to dual immune checkpoint blockade.

Several oral abstracts presented at the American Society of Clinical Oncology’s annual meeting highlight ongoing research of Keytruda, Opdivo, Tecentriq and more in skin cancer.

Encorafenib and binimetinib show promise in reducing recurrence risk for high-risk BRAF V600-mutant melanoma, demonstrating a ...

Green chemistry isn’t always top of mind for industrial drug discovery chemists. This 4-point plan can get it there ...

Dr. Dinarello has trained over 50 medical investigators, many of whom are recognized as experts in their fields of medicine. The Institute for Science Information has listed Dr. Dinarello as the world ...

The FDA has approved darolutamide without chemotherapy for treatment of metastatic hormone-sensitive prostate cancer.The FDA ...